title: Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and beta-chemokine production.
abstract: Susceptibility of PHA/rIL-2-stimulated PBMC from 14 healthy blood donors for NSI HIV-1 infection was analyzed in relation to CCR5 expression and beta-chemokine production. After 1 week of culture in the presence of rIL-2, but not at the moment of inoculation, CCR5 surface expression was positively and beta-chemokine production was inversely associated with susceptibility to NSI HIV-1 infection. Surprisingly, no association was observed between CCR5 genotype and in vitro NSI HIV-1 susceptibility, which was in agreement with similar levels of CCR5 surface expression and beta-chemokine production in CCR5Delta32/+ and CCR5 +/+ PBMC after PHA/rIL-2 stimulation. In contrast to what was observed in vitro, CCR5 genotype did associate with CCR5 surface expression levels in vivo in resting as well as in activated CD4(+) T cell populations that were identified by the expression of CD45RO, CD27, HLA-DR, and CD69. The association between CCR5 expression and susceptibility to infection by NSI HIV-1 observed in vitro might offer an explanation for the in vivo observed protective effect of CCR5 polymorphisms that influence CCR5 expression on disease progression.
authors.affiliation: Department of Clinical Viro-Immunology, CLB and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Academic Medical Center, Amsterdam, Plesmanlaan 125, Amsterdam, 1066 CX, The Netherlands.
authors.forename: H
authors.initials: H
authors.lastname: Blaak
authors.forename: L J
authors.initials: LJ
authors.lastname: Ran
authors.forename: R
authors.initials: R
authors.lastname: Rientsma
authors.forename: H
authors.initials: H
authors.lastname: Schuitemaker
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D016827:CD8 Antigens / Q000378:metabolism; D019742:Chemokines, CC / Q000378:metabolism*; D005838:Genotype; D015497:HIV-1 / Q000254:growth & development*; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000378:metabolism* / Q000821:virology; D010835:Phytohemagglutinins / Q000494:pharmacology; D019713:Receptors, CCR5 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D016827:CD8 Antigens; D019742:Chemokines, CC; D007376:Interleukin-2; D010835:Phytohemagglutinins; D019713:Receptors, CCR5; D011956:Receptors, Cell Surface; D011994:Recombinant Proteins